New horizons in lung cancer management through ATR/CHK1 pathway modulation

被引：52

作者：

Thapa, Riya ^{[1
]}

Afzal, Obaid ^{[2
]}

Bhat, Asif Ahmad ^{[1
]}

Goyal, Ahsas ^{[3
]}

Alfawaz Altamimi, Abdulmalik Saleh ^{[2
]}

Almalki, Waleed Hassan ^{[4
]}

Alzarea, Sami, I ^{[5
]}

Kazmi, Imran ^{[6
]}

Singh, Sachin Kumar ^{[7
,8
]}

Dua, Kamal ^{[8
,9
]}

Thangavelu, Lakshmi ^{[10
]}

Gupta, Gaurav ^{[1
,11
]}

机构：

[1] Suresh Gyan Vihar Univ, Sch Pharm, Mahal Rd, Jaipur, India

[2] Prince Sattam Bin Abdulaziz Univ, Coll Pharm, Dept Pharmaceut Chem, Al Kharj 11942, Saudi Arabia

[3] GLA Univ, Inst Pharmaceut Res, Mathura, UP, India

[4] Umm Al Qura Univ, Coll Pharm, Dept Pharmacol, Mecca, Saudi Arabia

[5] Jouf Univ, Coll Pharm, Dept Pharmacol, Sakaka, Al Jouf, Saudi Arabia

[6] King Abdulaziz Univ, Fac Sci, Dept Biochem, Jeddah, Saudi Arabia

[7] Lovely Profess Univ, Sch Pharmaceut Sci, Phagwara 144411, India

[8] Univ Technol Sydney, Fac Hlth, Australian Res Ctr Complementary & Integrat Med, Ultimo, NSW 2007, Australia

[9] Univ Technol, Discipline Pharm, Grad Sch Hlth, Sydney, NSW 2007, Australia

[10] Saveetha Univ, Saveetha Inst Med & Tech Sci, Saveetha Dent Coll & Hosp, Dept Physiol,Ctr Global Hlth Res, Kuthambakkam, India

[11] Graphic Era Hill Univ, Sch Pharm, Dehra Dun 248007, India

来源：

FUTURE MEDICINAL CHEMISTRY | 2023年

关键词：

ATR; cancer; CHK1; DNA damage; lung cancer; NSCLC; SCLC; DNA-DAMAGE RESPONSE; ATR; INHIBITION; CHK1; AXIS; THERAPY; STRESS; REPAIR; CELLS; PP2A;

D O I：

10.4155/fmc-2023-0164

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Lung cancer is the leading cause of cancer-related deaths worldwide. Molecular profiling has contributed to a new classification of lung cancer, driving advancements in research and therapy. The ataxia telangiectasia and rad3/checkpoint kinase 1 (ATR/CHK1) pathway plays a crucial role in maintaining genomic stability, and its activation has been linked to the development of lung cancer, drug resistance and poor prognosis. Clinical and preclinical studies have demonstrated promising results in targeting this pathway. ATR and CHK1 are proteins that collaborate to repair DNA damage caused by radiation or chemotherapy. ATR/CHK1 inhibitors are currently under investigation in preclinical and clinical trials. This article explores the ATR/CHK1 pathway and its potential for treating lung cancer.

引用

页码：1807 / 1818

页数：12